12:00 AM
Mar 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Humira adalimumab: Phase III started

Abbott began the double-blind, placebo-controlled, international Phase III M11-313 and M11-810 trials to evaluate subcutaneous Humira given weekly or every other week for up to 36 weeks in a total of about 600 patients with moderate to severe hidradenitis suppurativa. The chronic, inflammatory skin disease is characterized by...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >